New Immunization Campaign Launches to Protect Infants from RS Virus
The Netherlands – A nationwide campaign to immunize infants against Respiratory Syncytial Virus (RSV) has begun, offering a new layer of protection against a leading cause of infant illness and strain on healthcare resources. the preventative measure,utilizing the monoclonal antibody Nirsevimab,aims to considerably reduce hospitalizations due to RSV,a virus that globally accounts for the most infant deaths after malaria.
While fatalities from RSV are rare in the Netherlands, the virus places a substantial burden on the healthcare system. Each year, 1,500 to 3,000 children are hospitalized with RSV infections, with approximately 150 requiring intensive care. This surge in cases frequently leads to the postponement of scheduled surgeries and necessitates emergency assistance from neighboring countries like Germany and Belgium. Early data from abroad,where Nirsevimab has been in use,indicates hospital admissions have decreased by around 80 percent.
Nirsevimab differs from traditional vaccination. It provides direct immunity by delivering antibodies to the baby, bypassing the need for the body to produce them independently. This offers almost immediate protection lasting approximately six months, and doctors report side effects are uncommon.
The rollout, managed by the RIVM (National Institute for public health and the Habitat), employs a flexible schedule. Infants born between October 1st and March 1st will receive the immunization within two weeks of birth. For babies born outside this timeframe, the immunization will be administered in september or October, just before the typical RSV season.
Pediatricians emphasize that Nirsevimab is available for all infants, and the campaign is expected to alleviate the annual pressure on hospitals caused by RSV infections.
